Before discovery of an effective vaccine,
Haemophilus influenzae type b (Hib) was the most important cause of bacterial meningitis, otitis media, pneumonia, cellulitis, bacteremia, and septic arthritis in infants and children younger than five years (
1,
2). It is a significant public health concern in many parts of the world, with as many as 3 million cases of serious disease occurring every year. The Hib capsule is its major virulence factor, and is composed of a polyribosyl ribitol phosphate (PRP) that can induce protective and effective immunity (
3). Hib PRP is a polymer of repeating monomeric units, structurally characterized as β-D-ribose-D-ribitol-phosphate (
4,
5). The first generation of vaccines for Hib was licensed in the United States in 1985, based on purified capsular polysaccharide (
6). This type of vaccine stimulates a T cell-independent immune response and prevents Hib infections in children older than 2 years, but it does not protect infants (
7). Since about 75% of Hib infection cases occur in children younger than 2 years, second-generation Hib vaccines, which induced T-cell dependent immune responses, were produced as PRP-protein conjugates and licensed in the United States in 1987 (
8). The price of the conjugated PRP vaccine is high (
9), and therefore a major challenge in Hib vaccine production is to develop a cost-efficient vaccine. To enhance biomass and PRP productions, most previous studies have focused on Hib cultivation with respect to essential chemical, biochemical, and physical factors such as pH, DOT (dissolved oxygen tension), aeration, temperature, and agitation (
10-
12). Most of these studies employed single factors or multiple factors by changing one variable at a time, while keeping the others at a constant level. However, such growth conditions do not mimic the natural bacterial growth condition, which is affected by simultaneous actions and interaction of the growth factors.